Fairvalue-Calculator Fairvalue-Calculator
EN DE

TaiMed Biologics Inc (4147) Fair Value & Analysis

Healthcare · TW · Market cap 15.7B TWD

Price63.40 TWD
Fair Value64.13 TWD
Upside+1.2%
Quality95/100
Evidence: Medium Range 48.10 TWD – 80.16 TWD

Fair value as of: Jun 24, 2026

Analysis

TaiMed Biologics Inc (4147) currently trades at 63.40 TWD, while our model-based Fair Value estimate is 64.13 TWD — implying the stock looks roughly 1.2% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates for cancer treatment. In addition, the company offers contract development and manufacturing services. It has a research and development agreement with Genentech and Biogen Inc. for Trogarzo TMB-355; and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is TaiMed Biologics Inc (4147) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 64.13 TWD versus a price of 63.40 TWD — about +1% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 4147?
Our 21-model fair value for TaiMed Biologics Inc is 64.13 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 63.40 TWD.
What is the quality score of 4147?
TaiMed Biologics Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.